YasminArafahMD

Hematology/Oncology

Physician

Dr. Arafah is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
8326 Naab Rd
Indianapolis, IN 46260
Phone+1 317-871-0000

Fax+1 317-871-0010

Dr. Yasmin Arafah is an internist in Indianapolis, IN. She received her medical degree from University of Jordan Faculty of Medicine and has been in practice 3 years. She specializes in hematology/oncology. She has 1 publication.

Indiana University School of MedicineFellowship, Hematology and Medical Oncology, 2021 - 2024
Case Western Reserve University/University Hospitals Cleveland Medical CenterResidency, Internal Medicine, 2018 - 2021
University of JordanInternship, 2015 - 2016
University of Jordan Faculty of MedicineClass of 2015

PubMed

409 citations
The hypercoagulable state in COVID-19: Incidence, pathophysiology, and management.
Mouhamed Yazan Abou-Ismail, Akiva Diamond, Sargam Kapoor, Yasmin Arafah, Lalitha Nayak
Thrombosis Research. 2020-06-20
5 citations
Outcomes of Immune Thrombotic Thrombocytopenic Purpura (iTTP) With Upfront Cyclophosphamide vs. Rituximab.
Mouhamed Yazan Abou-Ismail, Yasmin Arafah, Pingfu Fu, Shufen Cao, Alvin H. Schmaier
Frontiers in Medicine. 2020-10-28
7 citations
Corrigendum to "The hypercoagulable state in COVID-19: Incidence, pathophysiology, and management" [Thromb. Res., 194, October 2020, Pages 101-115].
Mouhamed Yazan Abou-Ismail, Akiva Diamond, Sargam Kapoor, Yasmin Arafah, Lalitha Nayak
Thrombosis Research. 2021-08-01

Abstracts/Posters

Outcomes after Treatment with Upfront Cyclophosphamide or Rituximab for Initial Acquired Thrombotic Thrombocytopenic Purpura
Yasmin Arafah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019